19318-84-4

Basic information

• Product Name: 1-allyl-3-(4-Morpholinophenyl)thiourea
• Synonyms: 1-allyl-3-(4-Morpholinophenyl)thiourea
• CAS NO: 19318-84-4
• Molecular Formula: C₁₄H₁₉N₃OS
• Molecular Weight: 277.38516
• Mol File: 19318-84-4.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 428.7°C at 760 mmHg
• Flash Point: 213.1°C
• Appearance: /
• Density: 1.202g/cm³
• Vapor Pressure: 1.48E-07mmHg at 25°C
• Refractive Index: 1.631
• CAS DataBase Reference: 1-allyl-3-(4-Morpholinophenyl)thiourea(CAS DataBase Reference)
• NIST Chemistry Reference: 1-allyl-3-(4-Morpholinophenyl)thiourea(19318-84-4)
• EPA Substance Registry System: 1-allyl-3-(4-Morpholinophenyl)thiourea(19318-84-4)

Safety Data

• Hazardous Substances Data: 19318-84-4(Hazardous Substances Data)

Usage

Type of compound

thiourea derivative

Substituents

morpholine group and allyl group

Potential pharmacological effects

anti-cancer activity, calcium signaling mediator

Potential applications

photonic applications due to nonlinear optical properties

Status of research

ongoing, of interest in the scientific community.

InChI:InChI=1/C14H19N3OS/c1-2-7-15-14(19)16-12-3-5-13(6-4-12)17-8-10-18-11-9-17/h2-6H,1,7-11H2,(H2,15,16,19)

Upstream product

• 2524-67-6 4-morpholino-4-yl-phenylamine 
• 51317-66-9 4-(4-isothiocyanato-phenyl)morpholine 
• 107-11-9 1-amino-2-propene 

Relevant articles and documents

Synthesis and biological evaluation of arylthiourea derivatives with antitubercular activity

Tuberculosis (TB) is a contagious disease caused by Mycobacterium tuberculosis (M. tuberculosis), and remains one of the most life-threatening plagues for public health in the world. The emergence of drug resistant strains of TB and co-infection with HIV has further complicated TB treatment. Here, the synthesis and characterizaton of a series of compounds were described, and these were followed by evaluating for their antibacterial activity against M. tuberculosis. Several novel arylthiourea derivatives exhibited excellent activity (lowest MIC=0.09 μg/ml) against M. tuberculosis including drug resistant strains of M. tuberculosis. The results suggest that these compounds are promising candidates for new anti-TB agent development.